May 3, 2022
Life Sciences
  • Pfizer Inc. said it expects its COVID-19 antiviral pill to bring in $22 billion in sales this year, while the vaccine it developed with BioNTech SE should bring in $32 billion, the first time the drugmaker has kept those sales forecasts level as demand begins to wane. Pfizer Chief Executive Albert Bourla said he expects to see increased access to the antiviral pill and more orders from governments “as the virus mutates and causes spikes in infections around the world.” (Article here)